Results 341 to 350 of about 260,030 (390)

Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront Resection. [PDF]

Int J Mol Sci
Zavrtanik Čarni H, Badovinac D, Blagus T, Goričar K, Ranković B, Matjašič A, Zupan A, Tomažič A, Dolžan V.   +8 more
europepmc   +1 more source

A disulfidptosis‐related gene signature predicts prognosis and immune‐metabolic landscape in multiple myeloma

British Journal of Haematology, EarlyView.
Summary Disulfidptosis is a newly recognized cell death induced by disulphide stress under glucose deprivation. However, its clinical implications in multiple myeloma (MM) remain largely unexplored. We identified disulfidptosis‐related genes via co‐expression analysis and developed a risk signature through univariate Cox, least absolute shrinkage and ...
Li Wang, Jinjin Wang, Yutong Wang, Ting Niu, Ailin Zhao   +4 more
wiley   +1 more source

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models. [PDF]

Cancers (Basel)
De Nobrega DD, Eiler LC, Ahirwar P, Nallapu S, Rawal UP, Crawford CL, Buchsbaum DJ, Keeton AB, Maxuitenko YY, Chen X, Piazza GA, Tsung A, Budhwani KI.   +12 more
europepmc   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how? [PDF]

Transl Lung Cancer Res
Nagasaka M, Khan HY, Luo F, Al-Hallak MN, Saif MW, Mohammad RM, Azmi AS.   +6 more
europepmc   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

British Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi, Reyhaneh Hooshmandabbasi, Alessandro Ravoni, Ying Ma, Luigi Manni, Timothy J. Koh, Caroline Maake, Tiziana Guarnieri, Darong Lai, Vitalii Zablotskii, Christine Nardini   +10 more
wiley   +1 more source

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC. [PDF]

Front Oncol
Tubita A, Fancelli S, Anela L, Petroni G, Caliman E, Mazzoni F, Scolari F, Napolitano B, Menicacci B, Comin CE, Voltolini L, Pillozzi S, Antonuzzo L.   +12 more
europepmc   +1 more source

Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions. [PDF]

Curr Treat Options Oncol
Peng C, Oberstein PE.
europepmc   +1 more source

A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer. [PDF]

Commun Biol
Wang S, Diao S, Kim H, Zou JY, Li KK, Koromilas AE.   +5 more
europepmc   +1 more source

Evaluating the Effect of <i>KRAS</i> Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. [PDF]

JCO Precis Oncol
Ebia MI, Blais EM, Cui Y, Petricoin EF, Pishvaian M, Gaddam S, Gong J, Osipov A, Hendifar AE.   +8 more
europepmc   +1 more source